Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors.

Lowndes, Sarah A; Adams, Avril; Timms, Anthony; Fisher, Nita; Smythe, Jon; Watt, Suzanne M; Joel, Simon; Donate, Fernando; Hayward, Carolyn; Reich, Steven; Middleton, Mark; Mazar, Andrew; Harris, Adrian L

Lowndes, Sarah A; Adams, Avril; Timms, Anthony; Fisher, Nita; Smythe, Jon; Watt, Suzanne M; Joel, Simon; Donate, Fernando; Hayward, Carolyn; Reich, Steven; Middleton, Mark; Mazar, Andrew; Harris, Adrian L.

Affiliation

Lowndes SA; Cancer Research UK Department of Medical Oncology, Churchill Hospital, Oxford, United Kingdom.

Clin Cancer Res ; 14(22): 7526-34, 2008 Nov 15.

Article in En | MEDLINE | ID: mdl-19010871

Subject(s)

Chelating Agents/adverse effects; Chelating Agents/pharmacokinetics; Chelating Agents/therapeutic use; Chelation Therapy; Choline/adverse effects; Choline/pharmacokinetics; Choline/therapeutic use; Copper/blood; Molybdenum/adverse effects; Molybdenum/pharmacokinetics; Molybdenum/therapeutic use; Neoplasms/drug therapy; Adult; Aged; Ceruloplasmin/drug effects; Cytokines/blood; Cytokines/drug effects; Endothelial Cells/drug effects; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Superoxide Dismutase/blood; Superoxide Dismutase/drug effects

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Chelation Therapy / Chelating Agents / Choline / Copper / Molybdenum / Neoplasms Type of study: Prognostic_studies Language: En Journal: Clin Cancer Res Year: 2008 Type: Article Affiliation country: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google